IVD China last week: Roche, Kindstar Global, Illumina, Novogene, Berry Genomics, GE Healthcare AND Eisai China

Roche Diagnostics, Zhongshan Hospital, and Dunwill Medical Advance NGS Digital Pathology

On November 6, at the 7th China International Import Expo (CIIE), Roche Diagnostics, Zhongshan Hospital (affiliated with Fudan University), and Dunwill Medical announced a partnership to develop a fully automated “Sample in, Result out” solution for Next-Generation Sequencing. The collaboration aims to drive clinical research, foster innovation, and accelerate the application of digital pathology technologies, contributing to the advancement of precision medicine.

Roche Diagnostics and Kindstar Global Collaborate on Lymphoma Precision Diagnosis Standardization

On November 6, at the 7th CIIE, Roche Diagnostics and Kindstar Global signed a Memorandum of Understanding to promote the standardization of precision diagnosis and treatment systems for lymphoma in China. This partnership will focus on enhancing diagnostic accuracy and consistency, advancing lymphoma care nationwide.

Roche Diagnostics and Healthsky Partner to Transform Pathology

On November 6, at the 7th CIIE, Roche Diagnostics announced a partnership with Hangzhou Healthsky to introduce a fully automated slide organizer. The collaboration aims to optimize pathology workflows, explore innovative business models, and deliver efficient, personalized precision medicine solutions for Chinese pathology laboratories.

Novogene and Illumina Deepen Partnership to Propel Gene Sequencing Innovation

On November 6, at the 7th CIIE, Novogene and Illumina signed a new agreement to strengthen their collaboration. The partnership focuses on advancing genomics applications in scientific research, clinical diagnostics, and public health. Together, they aim to drive innovation in gene sequencing and expand its accessibility across diverse sectors.

Berry Genomics and Illumina Collaborate on NovaSeq X Plus Project

On November 6, at the 7th CIIE, Berry Genomics and Illumina announced a strategic partnership centered on the NovaSeq X Plus high-throughput sequencer. This collaboration marks a significant milestone in their ongoing efforts to accelerate technological innovation and drive the adoption of gene sequencing in China. Gao Yang, Chairman and General Manager of Berry Genomics, attended the signing ceremony.

Eisai China and GE Healthcare Unite to Advance Alzheimer’s Diagnosis and Treatment

On November 7, at the 7th CIIE, Eisai China and GE Healthcare signed a strategic cooperation memorandum. The partnership combines expertise in neurology, imaging, and innovative drug therapies to enhance early detection and precision diagnosis of Alzheimer’s Disease (AD). The collaboration will focus on clinical research, optimizing diagnostic pathways, and improving patient awareness and access, aiming to create an integrated precision diagnosis and treatment ecosystem for AD. This initiative seeks to improve patient outcomes and quality of life for those affected by the disease.